Drug Profile
Research programme: pain therapeutics - NAEJA
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator NAEJA Pharmaceutical
- Developer AstraZeneca; NAEJA Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Canada
- 29 Feb 2008 Preclinical development is ongoing